TGFB1 and osteogenesis imperfecta: Continuous administration of 0.6 g/L losartan via the drinking water for 28 days reduced serum TGFβ concentrations from 79.2 ± 14.6 ng·ml to 60.0 ± 18.6 ng/ml (P < 0.05) confirming that inhibiting the angiotensin receptor in OI mice effectively reduces TGFβ secretion (Fig. 2A).